Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents

Diagnostic Microbiology and Infectious Disease

Volumn 52, Issue 3, 2005, Pages 181-186

  Sader, Helio S ^a   Jones, Ronald N ^a,b   Stilwell, Matthew G ^a   Dowzicky, Michael J ^c   Fritsche, Thomas R ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Bloodstream infection; Nosocomial infection; Straphylococcus aureus; Tigecycline

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROBACTER; ESCHERICHIA COLI; HOSPITAL INFECTION; INFORMATION PROCESSING; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 23644443232     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.05.005     Document Type: Article

References (19)

1. G. Bauer, C. Berens, S.J. Projan, and W. Hillen Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA J. Antimicrob. Chemother. 53 2004 592 599
2. D.J. Biedenbach, M.L. Beach, and R.N. Jones In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive bloodstream infection isolates and strains producing extended-spectrum β-lactamases Diagn. Microbiol. Infect. Dis. 40 2001 173 177
3. D.J. Biedenbach, G.J. Moet, and R.N. Jones Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) Diagn. Microbiol. Infect. Dis. 50 2004 59 69
4. P.A. Bradford Tigecycline: a first in class glycylcycline Clin. Microbiol. Newsl. 26 2004 163 168
5. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, 15th informational supplement, M100-S15 2005 CLSI Wayne, PA
6. T.R. Fritsche, and R.N. Jones Antimicrobial activity of tigecycline (GAR-936) tested against 3,498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections Int. J. Antimicrob. Agents 24 2004 567 571
7. T.R. Fritsche, J.T. Kirby, and R.N. Jones In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections Diagn. Microbiol. Infect. Dis. 49 2004 201 209
8. A.C. Gales, and R.N. Jones Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates Diagn. Microbiol. Infect. Dis. 36 2000 19 36
9. E.H. Ibrahim, G. Sherman, S. Ward, V.J. Fraser, and M.H. Kollef The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 118 2000 146 155
10. R.N. Jones Disk diffusion susceptibility test development for the new glycylcycline, GAR-936 Diagn. Microbiol. Infect. Dis. 35 1999 249 252
11. M.D. Kitzis, A. Ly, and F.W. Goldstein In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae Antimicrob. Agents Chemother. 48 2004 366 367
12. D. Milatovic, F.J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob. Agents Chemother. 47 2003 400 404
13. G. Muralidharan, M. Micalizzi, J. Speth, D. Raible, and S. Troy Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects Antimicrob. Agents Chemother. 49 2005 220 229
14. D. Nathwani Tigecycline: clinical evidence and formulary positioning Int. J. Antimicrob. Agents 25 2005 185 192
15. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition Approved document M7-A6 2003 NCCLS Wayne, PA
16. R. Patel, M.S. Rouse, K.E. Piper, and J.M. Steckelberg In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae Diagn. Microbiol. Infect. Dis. 38 2000 177 179
17. Tygacil Product Insert June, 2005 Wyeth Pharmaceuticals Inc Philadelphia (PA)
18. M.P. Weinstein, M.L. Towns, S.M. Quartey, S. Mirrett, L.G. Reimer, G. Parmigiani, and L.B. Reller The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology and outcome eof bacteremia and fungemia in adults Clin. Infect. Dis. 24 1997 584 602
19. G.G. Zhanel, K. Homenuik, K. Nichol, A. Noreddin, L. Vercaigne, J. Embil, A. Gin, J.A. Karlowsky, and D.J. Hoban The glycylcyclines: a comparative review with the tetracyclines Drugs 64 2004 63 68